UBS Group
NMRA icon

UBS Group’s Neumora Therapeutics NMRA Stock Holding History

UBS Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,000
Closed -$127K – 10561
2024
Q4 		$127K Buy
+12,000
New +$144K ﹤0.01% 6725

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's NMRA Position: Q2 2026 in Review

UBS Group increased its Neumora Therapeutics (NMRA) stake by 141% in Q2 2026, buying an estimated $160K and bringing the position to 143,725 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #6687.

UBS Group first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $13.2M in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • UBS Group held 143,725 shares of Neumora Therapeutics worth $244K as of Q2 2026.
  • UBS Group bought 84,141 Neumora Therapeutics shares in Q2 2026, an estimated $160K.
  • Neumora Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6687 holding.
  • UBS Group first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • UBS Group's Neumora Therapeutics position peaked at $13.2M in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.